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Type 2 diabetes is a devastating disease that has been rising in prevalence in the 
United States over the last 70 years, a rise which has paralleled the obesity epidemic and 
use of artificial sweeteners. This is especially concerning due to the many detrimental 
comorbid complications stemming from this potentially longstanding disease, including 
retinopathy, nephropathy, and neuropathy. Xylitol is an alternative sweetener that has 
been gaining popularity due to its intense sweetening power, as well as reported 
antidiabetic effects. Studies on rats induced with type 2 diabetes have found that xylitol 
helps in reducing blood glucose and insulin secretion, as well as increase protein and fat 
metabolism, post prandial satiety, and oxygen free radical destruction. These promising 
results have provided ample evidence to test the effects of xylitol on humans. The 
proposed study will examine the results of daily xylitol intake (0%, 2.5%, 5%, and 10%) 
on blood sugar levels over 1 year in newly diagnosed type 2 diabetics. Plasma samples 
will be taken 3 times during the study period to examine HbA1c, fasting blood glucose, 
Glucagon-Like Peptide 1, Cholecystokinin, and Superoxide Dismutase. At the end of 1 
year of treatment, patient samples will be averaged into 6 month and 12-month results for 
each parameter and compared using ANOVA and student T-tests.  We will test whether 
the results of this study mirror those seen in previous research on rats, that the 
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antidiabetic effects of xylitol increase relative to concentration. This study hopes to 
provide further evidence on the need for xylitol supplementation in the diet of type 2 
diabetics, either independently or to augment medical treatment, in helping to prevent 
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 Type 2 diabetes has risen in prevalence within the United States over the last 
century. According to CDC data, the number and percentage of the U.S population 
diagnosed with type 2 diabetes has shown a consistent increase since 1958 (Figure 1).1 In 
2008 it was found that the national prevalence of diabetes was increasing in parallel with 
rates of obesity (Figure 2).2 Obesity is characterized by an elevated body mass index 
(BMI), a patient’s weight in kg divided by their height in meters squared (BMI= kg/m2). 
Patients are considered overweight if their BMI is between 25-30 and obese if their BMI 
is >30.3 The American Diabetes Association (ADA) recommends that all patients who 
are >18 years old with a BMI >25 be screened for type 2 diabetes.2 Screening is 
performed using hemoglobin A1c, a measure of the percent of hemoglobin in the blood 
with glucose attached averaged over the past 2-3 months, with a value >6.5% indicating 
diabetes.4 






Figure 2: Prevalence of diabetes and obesity in the US 1994-2008 adapted from Barnes2 
 
 
Worldwide retrospective studies on the origins of the type 2 diabetes epidemic 
support the hypothesis of a link between poor diet and the disease. During the First and 
Second World Wars there was a decline in diabetes mortality rates in European countries 
such as Germany due to food shortages and famine. Additionally, there was no change in 
diabetes mortality in countries that did not experience these shortages, such as those in 
North America.5 The rise in the United States of individuals diagnosed with this disease 
was most notable in the 1990s wherein there was a sharp increase in 1997 with 3.8% and 
10.11 million people diagnosed; this trajectory has continued to present day.1 Evidence 
suggests a link between the intake of soft drinks with obesity and type 2 diabetes 
resulting from the large amounts of high fructose corn syrup used in manufacturing.5 
High fructose corn syrup, a liquid sweetener alternative to sucrose, was first introduced to 
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the food and beverage industry in the late 1960s but grew in popularity between the mid 
1970s-1990s. It has been found to raise blood glucose and BMI to dangerous levels.6 
Type 2 diabetes is a disease associated with severe complications that can affect a 
patient’s health, productivity, and quality of life. More than 50% of patients with this 
disease will die of cardiovascular complications. It is a major cause of end stage renal 
disease, as well as a major cause of blindness and lower limb amputations. Many of the 
risk factors for type 2 diabetes are reversible including diet, physical activity, and 
smoking.5 The use of artificial sweeteners as sugar substitutes has paralleled the rise in 
obesity, with there being a strong link between obesity and onset of type 2 diabetes. This 
has paved the way for research into alternative natural sweeteners as dietary replacements 
to reduce the prevalence and morbidity of the disease. 
  
Statement of the Problem 
 Treatment for type 2 diabetes includes oral medications and injectable agents, all 
with the goal of reducing hemoglobin A1c levels to ~ 7%.7 These therapies target 
hyperglycemia, delay gastric emptying, increase insulin sensitivity in muscle and liver 
tissue, and increase glucose secretion by the kidneys.8 However, studies have found that a 
healthy lifestyle including diet and exercise can have a profound impact on the trajectory 
of the disease and even help prevent disease onset in at risk individuals.7,9,10 Artificial 
sweeteners on the market, such as saccharine, aspartame, and sucralose, are popular 
among overweight individuals and those suffering from metabolic syndrome and even 
type 2 diabetes. Sugar alcohols, like xylitol, are a simple dietary substitute and have been 
 
4 
reported as superior natural sweeteners due to their low calorific value, protective effects 
against cariogenicity, and potent antidiabetic effects on health.11 
 In order to further investigate the beneficial aspects to these natural sweeteners on 
overall health and in diabetes, rodents have been the primary study population. It can take 
years for diabetic complications to develop so representative animal models are used to 
assess interventions in much shorter time spans.12 Sprague-Dawley rats have been at the 
forefront of animal study subjects since streptozotocin treatment can induce a similar 
diabetic outcome to that seen in humans. However, no known single species is exactly 
equivalent to humans and the diabetic state we experience.13  
A clinical benefit has been found in rat models for the use of polyols like xylitol 
on the diabetic condition and, thus, a next step is examination of the effects in human 
subjects. Studies on human volunteers to date have been designed with small study 
populations and limited analysis to short term metabolic parameters of supplementary 
xylitol.14 Future research points in the direction of large scale randomized controlled 
studies with a focus on the long term effects that daily xylitol use can have on the 
outcome of patients suffering from type 2 diabetes. 
 
Hypothesis 
Xylitol is a natural sugar substitute that has been shown to have antidiabetic 
health benefits in rats induced with type 2 diabetes, including improvements in simple 
carbohydrate metabolism. This evidence suggests that xylitol supplementation in the diets 
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of humans with type 2 diabetes will lead to improvements in fasting blood glucose, 
HbA1c, GLP-1, CCK, and SOD.  
 
Objectives and specific aims 
 The increase in type 2 diabetes in the United States is a major public health issue 
that can be linked to the obesity epidemic. Focus should be placed on dietary alterations 
and options to help delay progression of the disease and even prevent its onset. Research 
on naturally occurring sugar alcohols, in particular xylitol, have shown this compound to 
be a promising sugar substitute that has many health benefits including altering metabolic 
mechanisms underlying type 2 diabetes.  
 
This thesis aims to: 
• Discuss and update the published scientific literature on the development and 
health outcomes of type 2 diabetes. 
• Review the current research that has been done on the health benefits of xylitol 
with a focus on carbohydrate metabolism. 
• Propose a large-scale research study to test the long-term effects of dietary xylitol 
supplementation on humans with type 2 diabetes
 
6 
REVIEW OF THE LITERATURE 
 
Overview 




Type 2 diabetes has become an American epidemic. The latest estimates from the 
American Diabetes Association (ADA) indicate that, in 2015, 30.3 million Americans 
had type 2 diabetes, an estimated 9.4% of the population. It was noted to be the 7th 
leading cause of death with 79,535 death certificates listing complications from the 
disease to be the primary cause of death and 252,806 certificates listing type 2 diabetes as 
a contributing factor. This disease is not only costly to the patient’s individual health but 
economically as well with an estimated $237 billion spent per year in direct medical costs 
and $90 billion lost in reduced national productivity.15 
 More concerning is the 84.1 million Americans aged >18 years in 2015 with pre-
diabetes. Of those, 1.5 million were eventually diagnosed with the disease.15 This is a 
staggering proportion as type 2 diabetes is a disease with slow onset and many 
preventable risk factors, primarily weight and inactivity. A greater percentage of fat 
tissue leads to a higher incidence of insulin resistance within that tissue and lack of 
activity only compounds the problem by reducing the amount of glucose cells require for 
energy. Furthermore, high blood pressure, abnormal lipid profiles, and high cholesterol 
not only frequently stem from obesity and low activity level but are alone strong risk 
factors for developing the disease. 16 Other non-preventable risk factors include race and 
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ethnicity with the highest prevalence found in American Indians and Alaskan natives at 
15.1% and non-Hispanic blacks at 12.7%.15 Age also plays a role in developing type 2 
diabetes; the risk increases for adults >45 years old.16 
 
Pathophysiology 
 The first notable research into diabetes began in 1936 when the British scientist 
Sir Harold P. Himsworth proposed the idea that there could be multiple types of diabetes 
based on insulin sensitivity.17 However, it was not until 1960 that Rosalyn Yalow and 
Solomon Berson at the Bronx VA Hospital in New York demonstrated that patents with 
adult-onset diabetes expressed higher than normal levels of circulating insulin.18 This 
showed that patients with what we understand now to be type 2 diabetes are not insulin 
dependent, since they can produce insulin; rather, their body is not responding to it 
correctly. 
 Insulin is a hormone generated by beta cells of the pancreas. Normally, insulin 
allows the body to absorb glucose into cells, where it can then be used for energy. 
Additionally, it helps the liver to store extra glucose as glycogen to be used during 
periods of fasting.19 Patients with type 2 diabetes develop insulin resistance, notably in 
peripheral muscle tissue and the liver. This leads to markedly reduced glucose uptake by 
those tissues and increased glucagon production by the pancreas resulting in 
glycogenolysis.20,21 An increase in fasting blood glucose will initially stimulate 
pancreatic beta cells to produce insulin but, as elevated blood glucose persists, the beta 
cells are unable to maintain an increased insulin output.20 This leads to beta cell burnout 
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and induced apoptosis.22 As a result, insulin ends up being disproportionately low in type 
2 diabetics relative to their plasma glucose concentrations.20,23 
Patients with type 2 diabetes are also found to have dysfunctional glucose uptake 
in the kidney and brain. In healthy individuals, if up to 180g of glucose is presented to the 
kidney per day, 100% will be reabsorbed back into the bloodstream. If this capacity is 
exceeded the extra glucose will be excreted into the urine.24 However, the kidneys of type 
2 diabetics have an increased capacity for glucose resorption, which further increases the 
plasma glucose concentrations.25 Additionally, after becoming insulin resistant the 
hypothalamus, which is associated with appetite regulation, experiences diminished 
inhibition of glucose ingestion.23 
 
Complications 
 The greatest cause of morbidity and mortality in type 2 diabetics stems from the 
health complications that follow years of high blood sugar. These patients are continually 
at risk for macro- and microvascular degeneration with macrovascular causing the 
majority of debilitating symptoms. Systemic late complications include diabetic 
nephropathy, neuropathy, retinopathy, atherosclerosis, and increased risk of infection.26 
Distal symmetric polyneuropathy occurs in 50% of patients 10 years following initial 
diagnosis and leads to the loss of sensation in distal extremities that progressively 
worsens.27 Retinopathy occurs 3-5 years after persistent hyperglycemia; scarring and 
retinal detachment results in end stage vision loss and glaucoma.28 
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 Damage to these tissues occur because cells of the retina, kidney, and nervous 
system are insulin-independent, meaning that when extracellular glucose levels rise the 
glucose can freely pass through the cell membrane. Glucose passes into the cell using  
GLUT/SLC2 transporters, which move glucose bidirectionally across the cell membrane 
relative to the extracellular glucose concentration.29 Within the cell, glucose is normally 
converted to fructose using the enzyme hexokinase, however, when this enzyme becomes 
saturated in states of hyperglycemia, glucose is instead converted to sorbitol by aldose 
reductase. This conversion requires the use of nicotinamide adenine dinucleotide 
phosphate (NADPH), depleting the cell’s stores available for use in the production of 
glutathione (GSH), which helps scavenge for reactive oxygen species (ROS).30 ROS 
create oxidative stress within the cells leading to damage. 
Oxidative stress is a disturbance in the balance of antioxidant and pro-oxidant 
factors. As more ROS are created, they begin to attack the structure of cells, causing them 
to lose their function. ROS arise from free radicals, which are naturally found within 
cells. They are short lived species that are important in activating different signaling 
pathways inside the cell that alter gene expression and coordinate cell death. In type 2 
diabetes, the mitochondria of cells increase production of energy from the elevated 
glucose load, consequently generating excess oxygen, which can receive unpaired 
electrons from the free radicals. The resulting ROS are very unstable and reactive, 




Since type 2 diabetes has become so prevalent, many therapies have been 
developed to slow progression of the disease and reduce the development of associated 
macrovascular complications. Therapeutic approaches can be categorized into two groups 
-- medication and lifestyle modification. Both, however, aim to achieve the same goal, to 
keep patients’ HbA1c levels as close to 7 as possible to reduce vascular comorbidities.31  
While the ADA and European Association For The Study of Diabetes (EASD) 
suggest that initial intervention focus on lifestyle changes, this can be difficult for 
patients to uphold longterm.32 For most patients drug therapy is indicated, which includes 
not only initial hypoglycemic agents but additional intensification strategies to maintain 
glycemic control over time, and encompasses drugs with differing mechanisms of action 
(Table 1).33 Such drugs include metformin, sulfonylureas, meglitinides, a-glucosidase 
inhibitors, and injectable agents, such as insulin.7,34–38  
 





Since type 2 diabetes has become so prevalent, many therapies have been 
developed to slow progression of the disease and reduce the development of associated 
macrovascular complications. Therapeutic approaches can be categorized into two groups 
-- medication and lifestyle modification. Both, however, aim to achieve the sam  goal, to 
keep patients’ HbA1c levels as close to 7 as possible to reduce vascular comorbidities.31 
 While the ADA and European Association For The Study of Diabetes (EASD) 
suggest that initial intervention focus on lifestyle changes, this can be difficult for 
patients to uphold longterm.32 For most patients drug therapy is indicated, which includes 
not only initial hypoglycemic agents but additional intensification strategies to maintain 
glycemic control over time, and encompasses drugs with differing mechanisms of action 
(Table 1).33 Such drugs include metformin, sulfonylureas, meglitinides, D-glucosidase 
inhibitors, and injectable agents, such as insulin.7,34–38 
Table 1: Type 2 diabetes medical management 
 Formulation Mechanism of Action Therapy 
Metformin Oral Inhibit gluconeogenesis by the 
liver 
-1st line agent 
-decreases fasting blood glucose 
by 20% 
-decreases HbA1c by 1.5% 
Sulfonylureas & 
meglitinides 
Oral Stimulate pancreatic beta cells to 
secrete insulin 
-2nd line agent 
-high efficacy and safety 
-meglitinides induce rapid insulin 




Oral Produce reversible inhibition of 
membrane bound intestinal D-
glucosidase enzymes causing 
delayed carb absorption and 
digestion 
-reduced post prandial glucose 
levels 
Thiazolidinediones Oral Increase insulin sensitivity by 
acting on muscle, adipose tissue, 
and liver 
-increase glucose utilization, and 





Lifestyle modifications, though difficult to adhere to long term, are extremely 
effective in treatment of the disease. Such modifications include increased sleep, reduced 
caloric intake, diet modifications, and increased exercise. Studies have found that 
sleeping less than 6 hours per night, which is increasingly prevalent in our society, 
increases insulin resistance, hypertension, hyperglycemia, and dyslipidemia. 
Furthermore, obese patients with diabetes should be counseled to reduce their caloric 
intake by 500–1000 kcal per day to aid in weight reduction, which will alone improve 
insulin sensitivity in tissues such as the brain, muscle, and liver.7 Since carbohydrates are 
a major source of glucose, patients who are on insulin therapy are also recommended to 
monitor their carb intake per day to better adjust their daily insulin dosing.9 It is 
preferable that intake of carbs come from fruits, vegetables, legumes, whole grains, and 
dairy as opposed to carb sources that also contribute salt, fat, or simple sugars.10 Studies 
have shown even a small 12 g/dl reduction in glycemic load is enough to reduce HbA1c 
levels by 0.3% per year.39 Lastly, it is suggested that patients exercise for a frequency of 
at least 3 days per week (the ideal is 5 days per week) with no more than 2 consecutive 
days of inactivity. Current recommendations are that even moderate exercise such as 
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RA-GLP1 Injectable  Increases glucose dependent 
insulin secretion, decreases 
secretion of glucagon, slows 
gastric emptying, promotes 
endothelium dependent artery 
relaxation, increases renal diuresis 
-increases satiety and reduces 
food intake 
-lowers blood pressure 
-reduces cardiovascular risk 
markers 
*short and long acting 
formulations 
Insulin Injectable  Shuttles glucose into cells for use -injected into fat under skin to be 
absorbed 
*short and long acting 
formulations 
  
Lifestyle modifications, though difficult to adhere to long term, are extremely 
effective in treatment of the disease. Such modifications include increased sleep, reduced 
caloric intake, diet modifications, and increased exercise. Studies have found that 
sleeping less than 6 hours per night, which is increasingly prevalent in our society, 
increases insulin resistance, hypertension, hyperglycemia, and dyslipidemia. 
Furthermore, obese patients with diabetes should be counseled to reduce their caloric 
intake by 500-1000 kcal per day to aid in weight reduction, which will alone improve 
insulin sensitivity in tissues such as the brain, muscle, and liver.7 Since carbohydrates are 
a major source of glucose, patients who are on insulin therapy are also recommended to 
monitor their carb intake per day to better adjust their daily insulin dosing.9 It is 
preferable that intake of carbs come from fruits, vegetables, legumes, whole grains, and 
dairy as opposed to carb sources tha  also contrib te salt, fat, or simple sugars.10 Studies 
have shown even a small 12 g/dl reduction in glycemic load is enough to reduce HbA1c 
levels by 0.3% per year.39 Lastly, it is suggested that patients exercise for a frequency of 
at least 3 days per week (the ideal is 5 days per week) with no more than 2 consecutive 
days of inactivity. Current recommendations are that even moderate exercise such as 
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walking for 20 min/day is beneficial. This is because the increase in insulin sensitivity 





 Another treatment option that will be the focus of this thesis is Xylitol.  Xylitol 
has been growing in popularity as an alternative natural sweetener in recent years, not 
only because of its low calorific value and intense sweetening power, but due to its potent 
antidiabetic effects as well. Sugar alcohols such as xylitol are a more appealing sugar 
substitute than currently used artificial sweeteners (AS) because, while similar in 
sweetness and caloric value, AS have been implicated in causing life threatening side 
effects with long term use, including lymphoma, leukemia, brain malignancy, chronic 
fatigue, headache, IBD, and adverse effects on GI microflora. Current and popular AS on 
the market are saccharine, aspartame, and sucralose. 11 
 Xylitol is a hydrogenated carbohydrate, otherwise known as a polyol. The 
distinction between sugars and polyols comes from the number of hydrogenated 
saccharides. Sugars can only be mono- or disaccharides, whereas polyols can be mono-, 
di-, or even polysaccharides, like xylitol. Because of its large size, xylitol can only 
diffuse from the small intestine into the circulation in low amounts, no more than 2% of 
the oral intake.39,41 Xylitol that is not absorbed in the small intestine is transported to the 
colon, where it is easily fermented due to its alcohol group by gut microbiota.39 This can 
lead to diarrhea and bloating with large amounts; however, many people have shown 
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tolerance to 10% ingestion.42 Xylitol that is absorbed into the bloodstream is sequestered 
in the liver, where it is dehydrogenated to xylulose and then converted to glucose which 
is slowly released back into circulation. This provides a regulated release of glucose, 
permitting the glucose metabolism pathway to not be overwhelmed.39 
 The antidiabetic qualities of xylitol include its low calorific value and reduced 
glycemic index compared to sucrose, as well as its reduced capacity to cause insulin 
secretion.39 Xylitol has 40% fewer calories than sucrose and a glycemic index of 7 
compared to 60-70 for sucrose. Since it causes a slow release of glucose into the 
circulation, it does not raise insulin levels significantly and, therefore does not contribute 
to insulin resistance. Additionally, xylitol has been shown to reduce osteoporosis and 
increase collagen production in healthy and diabetic populations.43,44 The protective 
health effects of xylitol will be further analyzed and discussed in the review of existing 
research. 
 
Current Models of Disease for Diabetes 
 In the study of the biological mechanisms of type 2 diabetes, as well as potential 
treatments like xylitol, rodent animal models have primarily been used. Laboratory 
animals such as mice and rats have the same set of physiological organs as humans with 
specific similarities to human metabolism. Many animal models for type 2 diabetes have 
been modified by diet or genetics to be obese to reflect the human condition of obesity- 
linked to disease development.13 In many mouse models the ob gene is expressed leading 
to severe diabetes with regression of pancreatic islets, hepatic glucose overproduction, 
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increased lipogenesis in the liver, and early death.45 Advantages of using mice are that 
their genome is 99% similar to the human’s and their small size allows for high 
throughput studies that are cost effective. While they have been successfully used to 
validate drug targets, they do not aim to fully model the human disease or mechanism.46 
For the proposed studies in this thesis, a significant limitation of the mouse model is that 
is does not demonstrate similarity to the pancreatic beta cell pathology observed in 
humans.12 
 Rats are the most commonly used rodent model for testing of type 2 diabetes, 
namely the Sprague-Dawley rat, a non-obese strain established in 1997 at Torri 
Pharmaceutical Co. in Japan. A distinct characteristic of these rats is the development of 
ocular complications, such as cataract and retinopathy with retinal detachment and 
hemorrhage, when diabetes is induced. Additionally, since they are able to survive longer 
with insulin treatment than mice, they are more useful for studying diabetic 
complications.47 Furthermore, they develop beta cell destruction that is closely related to 
the pathology seen in humans with type 2 diabetes.12 
Diabetes is induced in these rats through the use of Streptozotocin (STZ). STZ 
causes breakage of DNA, which results in increased activity of poly-ADP ribose 
synthetase, an enzyme that leads to energy deficiency and, ultimately, death of beta cells 
of the pancreas. Animals injected with STZ develop moderate and stable non-fasting 
hyperglycemia without significant change in plasma insulin level.48 This provides a good 
opportunity to investigate diabetes in a physiologically similar pathway to that found in 
humans.49 The rat model offers many advantages over the mouse including its larger size, 
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which allows for surgical procedures and drug administration in precise anatomical areas. 
Similar to the physiological responses in humans, the rat is modified by environmental 
agents such as toxins, stress, and diet.50 
 Animal models of diabetes mellitus are useful tools for studying the 
pathophysiology and clinical aspects of the disease because it would be impossible to test 
compounds on humans without a clear toxic profile or mechanism of action.13 
Furthermore, it takes years for diabetic complications to develop  in humans. Thus, it is 
incredibly valuable to use representative animal models for which interventions can be 
assessed in much shorter time spans.12 While no known single species is exactly 
equivalent to human type 2 diabetes, each model acts as an essential tool for investigating 
the genetic, endocrine, metabolic, and morphologic changes in the disease. However, in 
diabetes research the use of inappropriate animal models has been identified as a 
common problem.13 Thus, primarily, there is a strong need for successful experimental 
products on animals, specifically rats, to be transitioned into human models. 
 
Existing research  
 To better understand how xylitol could impact the overall course of type 2 
diabetes, focus must be placed on the metabolism of xylitol within the body and how it 
elicits a different response than that of sucrose. One study began by investigating induced 
hormonal release and gastric emptying time after ingestion of polyols, such as xylitol.51 
The metabolic action of sucrose and sugar substitutes begin at the sweet taste receptor. 
These receptors are located in the oral cavity and gut and are important in the control of 
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eating behavior and regulation of energy homeostasis by triggering regulatory circuits 
when bound. These receptors are also found on enteroendocrine cells of the small 
intestine, which upon activation will release a cascade of insulin, cholecystokinin (CCK), 
glucagon-like peptide-1 (GLP-1), inhibition of gastric emptying, and reduction of food 
intake.51  
Wolnerhanseen et al. tested the effects xylitol had on this hormonal pathway in 
lean and obese humans. Their study design used 10 lean volunteers (5 men and 5 women, 
mean BMI 21.7, mean age 24.6 years) and 10 obese volunteers (5 men and 5 women, 
mean BMI 40.0, mean age 27.2 years), all of whom were in general good health, did not 
smoke or use medications daily, and had no history of medical or psychiatric conditions. 
The sample size was chosen to be between 8-12 subjects to allow for a >50% detection of 
difference in parameters. The study period for each participant was 24 hours and on the 
day of the study each participant was randomized to either 75mg/300ml xylitol or glucose 
study intervention. The test solution also contained 13C reactive sodium acetate, which is 
absorbed in the small intestine and then exhaled as CO2. This permitted measurement of 
gastric emptying without exposing participants to radiation.42 
 The study found that xylitol was effective in binding to the sweet taste receptor on 
enteroendocrine cells and induced an increase in release of GLP-1 and CCK. CCK 
increased to 5.1 0.6 pmol/l after xylitol ingestion compared to the increase of 3.3 0.4 
pmol/l after glucose ingestion. GLP-1 increased to 11.5  1.1 pmol/l after treatment with 
xylitol compared to a rise of 10. 9 0.1 after treatment with glucose. These hormones are 
in part responsible for the reduced gastric emptying and increased satiety noted among 
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the study participants. Additionally, since the digestion of xylitol leads to small blood 
glucose release, there was very little insulin response. This was most apparent in the 
obese subject population where insulin rose to 100u/mL after glucose ingestion but only 
to 30 u/mL after xylitol ingestion; furthering the belief that this patient group might 
particularly benefit from polyols as sugar substitutes.42  
While the results of this study helped to shed light on the hormonal effects of 
xylitol, several significant limitations existed -- firstly the absence of diabetic study 
participants. Obesity is strongly linked to type 2 diabetes, however, the volunteers in this 
study were chosen for their lack of comorbid conditions and. Thus, are not representative 
of the disease population. In addition, the mean age of participants was mid-20s, roughly 
20 years younger than the average age in the population when type 2 diabetes becomes a 
significant threat. Additionally, participants were given a 16% dose of xylitol, which 
caused diarrhea and bloating in 70% of subjects. This dose is very high and not realistic 
in daily use; research has shown max tolerability to be around 10%.39 The study was also 
limited in the short duration of therapeutic intervention and data collection and more 
studies are needed to assess the gut hormone response to long term xylitol use. 
Altogether, these limitations make this study inconclusive. 
 Metabolic differences between sucrose and xylitol that exist in lipid synthesis and 
breakdown must be considered. When mammals have an excess of carbohydrates in their 
diet, those that cannot immediately be broken down into glucose are stored as glycogen, a 
majority of which is stored in the skeletal muscle and the liver. However, when glycogen 
stores are filled, de novo lipid synthesis can contribute to glucose disposal, which 
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promotes accumulation of visceral fat often seen in type 2 diabetes.52 Amo et al. designed 
a study using 18 Sprague-Dawley rats that were each fed a high fat diet. 12 rats were also 
fed xylitol in addition to their diets: 1g/100kcal or 2g/100kcal (6 rats for each 
concentration). Food intake and body weight was recorded daily for 8 weeks, after which 
blood samples were collected and all animals were euthanized by exsanguination. Results 
were expressed as means  SEM and significance of difference was determined by 
ANOVA.53 
 The study found that it is the impaired ability to increase fat oxidation in response 
to a high fat diet that leads to obesity and insulin resistance. Accumulation of visceral fat 
was significantly smaller in the xylitol fed groups compared to control with mean body 
weight (g/kg) in the xylitol fed groups to be 84.2 5.3 and 81.74.2 respectively with the 
high fat diet (HFD) group at 96.7 3.8.  The relative weight of mesenteric fat was also 
significantly lower between HFD and xylitol groups by 23.2%. The authors theorized this 
was due to xylitol’s effect on expression of PPAR, which is active in adipose tissue and 
triggers adipocyte differentiation and lipolysis. It also upregulates expression of 
adiponectin, an important modulator of insulin sensitivity and stimulation of fatty acid 
oxidation in the liver. Because of these beneficial effects, high levels of PPAR may help 
reduce visceral fat accumulation. Amo et al. found that PPAR was significantly 
upregulated in the xylitol fed group.53. 
 Xylitol has also been found to act on the SREBP-1c pathway. In the liver, 
transcription factor SREBP-1c is up-regulated by insulin and causes lipogenesis.54 In 
Amo et al, xylitol was given 30min after sucrose administration, which reduced insulin 
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levels (Figure 3).53 Xylitol’s ability to post-prandially reduce insulin secretion through 
co-administration may be a factor in helping to reduce overall visceral fat as well.  
Figure 3: Plasma glucose levels (A) and plasma insulin levels (B) post sucrose +/- xylitol  
or mannitol treatment, adapted from Amo et al.53 
 
Sucrose only (S), sucrose + xylitol (SX), sucrose + mannitol (SM) 
With the longest study period of xylitol feeding, the results could shed some light 
on long-term health benefits of xylitol. However, while this study showed effects in 
healthy rats, it is important to repeat this test in streptozotocin-induced diabetic rats. 
Further studies also need to be done to understand the mechanism in which xylitol 
triggers increased expression of PPAR.  
Although type 2 diabetes is characterized by partial loss of pancreatic beta cells, 
complications in organs such as the liver, kidney, and heart are in part due to tissue 
destruction from reactive oxygen species. A team at the University of KwaZulu-Natal in 
South Africa under the guidance of Dr. Islam permed studies to better understand the 
effect of xylitol on the antioxidant defense system of healthy and diabetic rats. This team 
focused on OH, NO, and Fe3+ antioxidant mechanisms of xylitol through in vitro and in 
vivo studies. 
The study population consisted of normal and streptozotocin induced diabetic rats 
that were given either water or 10% xylitol ad libitum for 5 weeks. At the end of the trial 
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period, the rats were euthanized and blood samples were collected via cardiac puncture 
and tissue samples from the liver, heart, pancreas and kidney were preserved for further 
analysis. ROS scavenging activity was then measured by spectrophotometry with 
differing concentrations of xylitol (1.25%, 2.5%, 5%, and 10%). Results were expressed 
as the mean  SD of 5-7 animals.55 
Electron donating and reducing abilities of bioactive compounds were 
demonstrated by the ferric reducing power, which is linked to antioxidant activity. The in 
vitro study found increasing reducing power observed with larger concentrations of 
xylitol. Furthermore, OH and NO scavenging ability had a similar trend with 
improvements were seen at 10% xylitol compared to 1.25%. OH scavenging activity in 
the 10% xylitol group was at 91.83%  1.13 as opposed to 78.71%  1.79 in the 1.25% 
xylitol group. This benefit is significant since OH is a major culprit in causing pancreatic 
beta cell damage in type 2 diabetics.55  
The in vivo results also indicated that feeding xylitol significantly increased the 
superoxide dismutase activity in all studied organs. Xylitol also increased the glutathione 
peroxidase activity in diabetic rats, which reduces the process of peroxidation. Diabetic 
rats treated with xylitol had kidney glutathione peroxidase activity (umol/min/ug protein) 
at 5.9 compared to just 3 in the diabetic control. Peroxidation allows for accumulation of 
reactive oxygen species, which disturbs the assembly of the cell membrane causing 
fluidity and permeability. This affects ion transport across the membrane which can 
inhibit metabolic processes.55 
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 A significant increase in activity of superoxide dismutase (SOD) and catalase in 
both diabetic and normal controls was found with xylitol feeding. SOD activity 
(umol/min/ug protein) in the pancreas was 2.75 in the diabetic rats fed xylitol compared 
to 1.9 in the diabetic control. Normal controls fed xylitol experienced an increase of 0.2 
in pancreatic SOD activity compared to normal control. Altogether the results of this 
study suggest a potent antioxidant property of the polyol in both normal and diabetic 
conditions.55  
However, additional research is needed to confirm that these results will be 
mirrored in humans. Also, the study design could be improved by administering xylitol in 
a more regulated fashion to remove confounding associated with rat behavior and thirst, 
since the test solution in this study was administered ad libitum. Future research could 
also extend the trial period to test more long-term dosing effects of xylitol on cellular 
antioxidant mechanisms. 
Along with ROS induced damage, post prandial hyperglycemia is an issue for 
type 2 diabetics and plays a major role in diabetic associated end organ complications. A 
large source of glucose in the diet is in the form of starch from carbohydrates. Glucose is 
produced by gastrointestinal hydrolysis of starch by -amylase and -glucosidase 
enzymes.56  It was hypothesized by Chuwuma et al. that a delay in digestion of 
carbohydrates into starch would then reduce post prandial glucose which causes 
hyperglycemia. They created a study to probe the effects of xylitol on carb digesting 
enzyme activity and further investigate intestinal and muscle glucose uptake.  
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In vitro, in vivo, and ex-vivo approaches were used to study normal and 
streptozotocin induced diabetic rats. The in vitro studies measured -amylase and -
glucosidase activity using different concentrations of xylitol. Results were measured via 
spectrophotometry. The ex-vivo study examined glucose absorption in the psoas muscle 
of rats and the in vivo study examined gastric emptying time. Both studies measured 
glucose absorption in the small intestine. Animals received either 10% xylitol + glucose 
or glucose alone, as well as phenol red. Phenol red was used to measure the gastric 
emptying and intestinal transit time. Results were presented as mean  SD.41 
Gastric emptying was significantly reduced after feeding of xylitol in diabetic and 
non-diabetic rats (Figure 4).41 Furthermore, xylitol lowered glucose absorption in the 1st , 
2nd , and 3rd quarters of the small intestine and distal colon when compared to normal 
controls. In the jejunum, glucose absorption (mg/cm jejunum) was 1.75  0.46 which was 
significantly different (P<0.05) from control (3.27  0.46). There was also significant 
potential of xylitol to improve psoas muscle glucose uptake with or without insulin.41  
Figure 4: Effects of xylitol on gastric emptying adapted from Chukwuma et al.41 
 
Post 1 hour experimental period. Normal control (NC), normal xylitol (NXYL),  




The in vitro studies found a dose dependent effect of xylitol on the activity of -
amylase and -glucosidase where increasing concentrations of xylitol reduced activity. 
Concentrations of 2628.99 mM xylitol resulted in 80% inhibition of -glucosidase 
compared to 164.31 mM xylitol which only showed 17% inhibition. When looking at -
amylase inhibition, 2628.99 mM xylitol caused 75% inhibition vs. <10% inhibition in 
164.31 mM xylitol supplementation.41 
Xylitol exhibits potential hypoglycemic, as well as anti-diabetic effects, by 
decreasing the activity of carbohydrate digesting enzymes and intestinal glucose 
absorption. These anti-diabetic effects are also enhanced by xylitol’s ability to delay 
gastric emptying and muscle glucose uptake.41 Future studies could include other organs 
with normally high glucose uptake such as the liver and brain.  
Because of the different ways in which the diabetic condition can induce tissue 
damage, namely by effects from hyperglycemia and ROS, it is necessary to determine 
whether xylitol can improve resulting end organ damage. Dr. Atiar Rahman and Dr. 
Shahdiul Islam answered this by testing the effects of different dosages of xylitol on 
healthy and diabetic rats. Partial pancreatic beta cell dysfunction was induced via 
streptozotocin and rats were confirmed diabetic if nonfasting blood glucose levels were 
>288mg/dl. Rats were randomized to receive either water or water with 2.5%, 5%, or 
10% xylitol and kept alive for 4 weeks, over which blood glucose levels were monitored 
weekly. In the last week of intervention, the animals were given an oral glucose tolerance 
test and then euthanized. Blood from cardiac puncture and tissues samples of the 
 
24 
pancreas and liver were taken for serum and histopathological studies. Results were 
expressed as mean  SD of 5-7 animals.11 
Rahman and Islam found that diabetic rats on 10% xylitol maintained 
significantly reduced blood glucose levels throughout the study and also responded better 
to the oral glucose tolerance test than diabetic animals treated with 2.5% or 5% xylitol. 
Over the 4 week intervention period, the rats fed 10% xylitol had non-fasting blood 
glucose level (mmol/L) of 12 compared to 23 in the diabetic controls. Furthermore, 
serum studies showed significantly decreased LDL and increased HDL in diabetic rats 
fed 10% xylitol compared to diabetic controls. Serum LDL (mg/dl) was found to be much 
lower (30 mg/dl) in 10% xylitol fed rats compared to diabetic controls (80 mg/dl). Serum 
HDL (mg/dl) was 12 in 10% xylitol treatment group and 8 in diabetic controls.11 
 This study population also found lower serum AST, LDH, CK-MB, and 
creatinine. These results confirm the hepato-, cardio-, and nephro-protective effects of 
10% xylitol. Importantly, tissue studies of the pancreas showed larger pancreatic islets 
with significantly higher numbers of beta cells indicating partial recovery of 















Figure 5: Pancreatic islet morphology adapted from Rhaman et al. 
 
Pancreatic islet size and beta cell count in normal and diabetic control rats as well as 
those treated with 2.5%, 5%, and 10% xylitol solution. Arrows point to islets.  
 
  Limitations within this study include the method of administration of xylitol since 
not all rats may have consumed the xylitol solution at the same rate or same total amount 
per day. Furthermore, rats were deemed diabetic after one non-fasting blood glucose 
measurement. As with human diagnosis, it would be important to obtain this 
measurement twice at different timepoints to confirm disease. Future studies will need to 
be done to test these effects of xylitol on pancreatic morphology and serum hepatic, renal, 
and cardiac markers in a human population.  
Xylitol has been found to have beneficial effects on gut hormone secretion, 
gastric emptying, and glycemic response as well as improvements in antioxidant defense, 
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pancreatic islet morphology, carbohydrate digesting enzyme activity, and reduced 
visceral fat accumulation. These crucial mechanisms help to slow the progression of type 
2 diabetes and prevent onset in at risk individuals. Xylitol has even been found to aid in 
skin and bone protection, which can be involved in systemic diabetic changes in late 
disease.  
Type 2 diabetics are at risk of foot ulcers, open wounds or sores that occur in 15% 
of patients. Of those who develop ulcers, 6% will be hospitalized because of infection 
and 85% of ulcers will precede amputation. These ulcers originate from neuropathy or 
vascular disease which occur due to elevated levels of blood glucose for prolonged 
periods of time.57  
A study performed by Knuuttila et al. found that diabetic rats had markedly 
reduced skin thickness at baseline compared to healthy rats but the reduction was much 
less in diabetic rats fed xylitol. Supplementation of diet with 10% xylitol in healthy and 
diabetic rats increased the amount of newly synthesized collagen, and healthy rats fed 
xylitol had a significant (P<0.01) increase of 29% in skin thickness compared to 
controls.44 These results point toward to the potential of xylitol to aid in the prevention of 
diabetic foot ulcers. 
Along with foot ulcers, patients with type 2 diabetes are at increased risk of 
osteoporosis as they age. The fracture risk in type 2 diabetics is increased because 
diabetics have reduced intestinal calcium absorption and decreased deposition of calcium 
in bone.43,58 These findings are mainly in trabecular bone including the tibia. A study 
performed by Mattila et al. found that tibia weight was lower in diabetic rats without 
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xylitol supplementation compared to control. Furthermore, trabecular bone volume was 
decreased by 47% in diabetic rats without xylitol in their diet compared to 13-20% in 
those with xylitol (Figure 6), a very dramatic effect that would be a major benefit in 
humans. Forty 3mo male rats were used with statistical difference between groups 
calculated using the unpaired t test with a P-value <0.001.43  
 
Figure 6: Proximal tibial changes in diabetes adapted from Mattila et al.43 
 
Proximal tibia of control (A), streptozotocin induced  
diabetic (B), 10% xylitol fed streptozotocin diabetic (C),  
and 20% xylitol fed streptozotocin diabetic (D). Increasing  
dose of xylitol helps to reduce loss of trabecular bone in the proximal tibia. 
 Type 2 diabetes is a devastating disease with many differing pathologies but also 
with many preventable risk factors. The systemic complications that occur from years of 
hyperglycemia lead to increased occurrence of morbidity and mortality which affect the 
patients, their families and the economy. Rising numbers of diabetic patients has led to an 
increase in healthcare costs and reduced productivity. By finding dietary modifications 
that can easily be incorporated into a patient’s daily life, a better outlook for this disease 
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can be achieved on the individual patient level and on a large scale, as a nation. Xylitol 
has been shown to be superior to sucrose and artificial sweeteners in metabolic 
parameters, glycemic index, and health outcomes. Although many of these studies have 
been done on rodents, namely rats, there is promise that similar if not identical benefits 
can be found in human populations as well. The growth of the type 2 diabetes epidemic 
calls for large scale and long-term studies in humans to test potential dietary 
















This will be a randomized controlled trial in which 100 volunteers with newly 
diagnosed type 2 diabetes whose blood sugar is not yet adequately controlled will be 
followed for 1 year taking either 0% (placebo), 2.5%, 5%, or 10% xylitol daily. Every 
other month (61 days) the patients will return to clinic to receive blood work that will 
assess specific carbohydrate metabolism parameters, as well as overall blood glucose 
levels. These parameters will include: hemoglobin A1c (HbA1c), fasting blood glucose 
(FBG), cholecystokinin (CCK), glucagon-like peptide 1 (GLP-1), and superoxide 
dismutase (SOD). During the treatment time period, patients will be asked to maintain a 
diet low in artificial sweeteners. Patients will fill out a questionnaire during each visit to 
assess how well they have been following a diabetic sensitive diet and note their exercise 
level. At the end of the year, data will be compiled for each parameter in each treatment 
group and averaged for visits 6mo and 12mo. This data will be analyzed via one-way 
ANOVA and student t-tests.  
 
Study population and sampling 
This study will recruit 100 volunteers between the ages of 20-60 yo who receive 
primary care at Boston Medical Center Family Medicine and have been newly diagnosed 
with type 2 diabetes. Diagnosis must be in accordance with the ADA diagnostic criteria 
which include: fasting glucose >126mg/dL, 2hr plasma glucose >200mg/dL during 75g 
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oral glucose tolerance test, random glucose 200mg/dL with symptoms of hyperglycemia, 
and HbA1c >6.5%. Patients’ blood sugar cannot be previously controlled or currently 
controlled with antidiabetic medication, either oral or injectable. Patients must not have 
any current neurological, cutaneous, or renal complications from the disease. They must 
not have been hospitalized within the last year and cannot be currently treated medically 
for comorbidities including hypertension (HTN), hyperlipidemia (HLD), chronic kidney 
disease (CKD), chronic heart failure (CHF), or cancer. Female patients cannot be 
pregnant or have plans to become pregnant. Patients must be willing to return to BMC bi-
monthly for blood work and completion of the diet/exercise questionnaire.  
  
Sample Size Parameters 
The total sample size of this trial was chosen based on the Diabetes and Ageing study 
performed by Laiteerapong et al.59 This study collected HbA1c percentages within the 
first year of T2DM diagnosis of 28,174 participants with a standard deviation of 
average HbA1c scores of 1.09. With this in mind and assuming an alpha level of 0.05, 
a sample size of 25 participants in each treatment group (making a total trial 
population of 100 participants) provides 80% power to detect an effect size of 0.88. 
The effect size was determined using the sample size calculator from UCSF Clinical 





Patients will be randomly allocated into the following 4 groups in a triple blind 
fashion with 25 patients in each group: placebo, 2.5% xylitol, 5% xylitol, and 10% 
xylitol. Patients will be given 500mg capsules daily which will contain only H20 or H20 
and xylitol in defined concentrations (Table 2). Capsule shells will be made of soft 
gelatin.  
Table 2: Concentrations of H20 and Xylitol in mg per 500mg capsule 
 H20 concentration  Xylitol concentration 
Placebo 500mg 0mg 
2.5% Treatment Group 487.5mg 12.5mg 
5% Treatment Group 475mg 25mg 
10% Treatment Group 450mg 50mg 
 
After randomization, patients will be provided a study identification number using 
a third party application. The subject identification number will then be registered in 
REDCap and all participant data collected at each timepoint throughout the study period 
will be entered into this electronic database. Subjects will be unblinded at the end of the 
study period or in a case of premature withdrawal from the study. 
 
Study variables and measures 
Initial study variables include the patient demographics (age, race, ethnicity, and 
gender) and this information will be pulled from BMC EMR data during trial registration 
and entered into REDcap. Patient daily diet and exercise are also variables and potential 
confounders since these factors alone can have an impact on overall blood sugar and 
management of type 2 diabetes. Participant diet and exercise will be assessed via an 
adapted Nutrition and Eating Habits Questionnaire from Howard University (Appendix 
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I).61 The questionnaire will be graded (Table 3, Appendix II) with 39 being the max 
amount of points accumulated. Any patient who scores >20pts on a questionnaire will be 
considered high risk of disease progression. Patient scores will be monitored over the 
year and averaged per treatment group at the end of the study.  
Table 3: Grading of adapted Nutrition and Eating Habits Questionnaire61 










13. *ungraded 19. 0pts=no 
1pt=yes 





14. 1pt for each 
food plan  
20. 0pts=no 
1pt=yes 
3. 1pt for each 
box 
checked 
9. 1pt for each 
meal eaten 
>4x away 





















6. 1pt=other 12. 0pts=no 
1pt=yes 
18. *ungraded   
 
Outcome variables for this study include the percentage of HbA1c. This variable 
is significant in its ability to measure average blood glucose levels over a 2-3 mo period. 
The sample source will be fasting plasma collected in a 4ml purple top EDTA tube at 
initial, 6mo, and 12mo visits. Fasting blood glucose is another important outcome 
variable in that it will measure how well the body is metabolizing and storing glucose. 
The sample source will be fasting plasma collected in a 4ml purple top EDTA tube at 
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initial, 6mo, and 12mo visits. Both HbA1c and fasting blood glucose are labs routinely 
measured at the BMC laboratory.   
Cholecystokinin (CCK) is a GI hormone responsible for stimulation of fat and 
protein digestion. The concentration of which is an important outcome variable and the 
sample source will be from fasting plasma collected in a 4ml purple top EDTA tube at 
initial, 6mo, and 12mo visit. This lab will be measured using the antibody T204 
radioimmunoassay technique described by Jansen et al62. In brief, CCK from plasma 
samples will be extracted using 90% ethanol prior to assay. The extracts will be dried and 
reconstituted to original volume in assay buffer. The accuracy in recovery of known 
amounts of CCK in plasma in prior studies have been approximately 0.5-3.1 pmol/l using 
the above described radioimmunoassay technique.   
Glucagon like peptide 1 (GLP-1) is a hormone released from intestinal epithelial cells 
that suppresses post-prandial glucose release, delays stomach emptying, and increases 
insulin release and sensitivity. This outcome variable will be the measurement of GLP-1 
concentrations in samples from fasting plasma collected in a 4ml purple top EDTA tube 
at initial, 6mo ,and 12mo visits. This lab will be measured using the radioimmunoassay 
technique described by Masuda et al.63  Plasma GLP-1 samples will be diluted with 
phosphate buffered saline and washed with methanol. GLP-1 will be eluted with 
ammonia and methanol. The elute will be collected, dried and hardened. Re-dissolution 
will occur with kit Assay Buffer, then GLP-1 concentrations in the sample will be 
measured. This method can detect samples with >2.0 pM active GLP-1.  
 
34 
Another outcome variable this study will examine is superoxide dismutase (SOD). 
SOD is an enzyme found within cells that catalyzes the breakdown of free radicals. The 
sample source will be from fasting plasma collected in 4ml EDTA tubes at initial, 6mo, 
and 12mo visits. SOD enzyme activity will be measured using the Cu/Zn ELISA kit from 
LSBio following the manufacturer’s protocol. The 96 well plate will be precoated with 
antibody and plasma samples will then be added to the wells where the target antigen will 
bind the antibody. Unbound sample will be washed away. A biotin-conjugated detection 
antibody is then added to bind the captured antigen. An Avian-Horseradish Peroxidase 
(HRP) conjugate will be added to bind the biotin. A TMB substrate will be added to react 
to the HRP enzyme which causes a color to develop. A sulfuric stop solution will be 
added to stop color development and the optical density of each well will be measured 
with a spectrophotometer.  
A potential confounding variable is urinary concentration of xylitol. This variable is 
significant in that it will allow a prediction of how much xylitol subjects are exposed to 
outside of the trial since xylitol can be easily accessed in the community due to its 
increasing popularity as an alternative sweetener. The sample for this source will be urine 
collected at 6mo and 12mo visits. Measurements will be detected by liquid 
chromatography-tandem mass spectrometry in a protocol outlined by Wamelink et al.64 
This technique will begin by desalting the urine samples using a mixed-bed ion-exchange 
resin. The sample will then be placed through an Aminex HPX-87C column to separate 
sugar isomers. Tandem mass spectrometry with an electron ion-spray source operating in 
the negative mode will be used to measure xylitol concentrations within the urine. 
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According to Livesay et al. 48% of daily xylitol ingested is absorbed in the small 
intestine, 50% is fermented by the gut microbiota in the large intestine, and <2% is 
excreted in the urine.39 Within each trial group it is expected that during urinalysis the 
placebo group should have 0 mg xylitol in the urine, the 2.5% treatment group should 
have 0.25 mg, the 5% treatment group should have 0.5 mg, and the 10% treatment group 




Patient charts from BMC family practice will be reviewed and patients who fit the 
inclusion criteria will be flagged. If already diagnosed with T2DM and deemed eligible 
per EMR review, they will be contacted via phone to speak about participation. If they 
agree they will be scheduled to come into the clinic at BMC where they will be formally 
consented, randomized, and begin the trial. 
BMC Family Medicine primary care physicians will also be educated about this trial 
and requested to notify study team if they diagnose a patient with T2DM who may fit the 
inclusion and exclusion criteria. Their chart will be reviewed while the patient is still in 
clinic to determine eligibility and, if so, the patient will be approached. They will then be 
consented, randomized, and begin the trial same day.  
 





Each visit cycle is 61 days with a study window of +/- 7 days. Patients will be 
incentivized to return to clinic for each study visit with a pre-paid bus pass to reduce the 
risk of premature study drop-out. At the end of each cycle patients will return any 
remaining xylitol capsules to study team.  
 
Study Schedule: 
Day 1 (Visit 1): 
This is the initial visit in which patients will visit with PCP for a physical exam to 
confirm T2DM diagnosis and rule out other comorbidities. The patient will then be 
consented to the study in clinic. Patient data will be entered into a 3rd party vendor 
database which will randomize the patient into a treatment group and provide them with a 
study number. Patient study number and demographics will then be entered into 
REDCap. Once the patient is entered into the database, they will receive initial fasting 
labs: Hba1c, fasting blood glucose, CCK, GLP-1, SOD (4 25ml purple top EDTA tubes 
[1 tube for Hba1c/FBG, 1 tube for CCK, 1 tube for GLP-1, 1 tube for SOD]). The patient 
will be provided with 68 days of xylitol capsules with concentrations corresponding to 
their treatment group. The soft shell gelatin capsules will have concentrations of either 
0%, 2.5%, 5%, 10% xylitol and H20.  
 
Day 61 (Visit 2) & Day 122 (Visit 3): 
During each visit on days 61 and 122, patients will return to clinic to complete the 
adapted Nutrition and Eating Habits questionnaire. They will return any extra xylitol 
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capsules not taken over each visit cycle. Patients will then be provided with 68 days of 
new xylitol capsules.  
 
Day 183 (Visit 4): 
During this visit the patient will meet with their PCP for a physical exam and to 
monitor development of further comorbidities. The Patient will receive fasting labs: 
Hba1c, fasting blood glucose, CCK, GLP-1, SOD (4 25ml purple top EDTA tubes). 
Urine will also be collected for measurement of xylitol excretion. The patient will 
complete the adapted Nutrition and Eating Habits questionnaire. They will return any 
extra xylitol capsules not taken over each visit cycle. Patients will then be provided with 
68 days of new xylitol capsules.  
 
Day 244 (Visit 5) & Day 305 (Visit 6): 
During each visit on days 244 and 305, patients will return to clinic to complete 
the adapted Nutrition and Eating Habits questionnaire. They will return any extra xylitol 
capsules not taken over each visit cycle. Patients will then be provided with 68 days of 
new xylitol capsules.  
 
Day 366 (Visit 7): End of Treatment: 
During this visit the patient will receive fasting labs: Hba1c, fasting blood 
glucose, CCK, GLP-1, SOD (4 25ml purple top EDTA tubes). Urine will also be 
collected for measurement of xylitol excretion. The patient will complete the adapted 
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Nutrition and Eating Habits questionnaire. They will return any extra xylitol capsules not 
taken over each visit cycle. The patient will meet with their PCP for a physical exam and 
to monitor development of further comorbidities and decide if medical treatment is 
needed moving forward. 
 
Data Storage in REDCap 
At the end of each study visit the following information will be entered into the REDCap 
database under each study participant’s personal record indicated by study identification 
number: Visit number and date, fasting lab collection time, fasting lab numeric results 
for: Hba1c, FBG, CCK, GLP-1, SOD, and questionnaire score. Free text boxes will be 




Data points at 6mo and 12mo will be the most clinically significant. Parameters 
(HbA1c, FBG, CCK, GLP-1, SOD) will be measured from plasma samples drawn during 
visits 4 and 7. Summary statistics will be performed by combining data between 
participants for each treatment group at 6mo and 12mo timepoints. This will result in a 
mean, median, and mode for each parameter at 6mo and 12mo for each treatment group. 
Omnibus statistics for each parameter will be performed comparing mean values between 
treatment groups at each time point using 1-way ANOVA. Results will be presented as 
mean  SD.  
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If the alternative hypothesis is accepted (there is a statistical difference between 
the means for at least 1 treatment group), then pairwise comparisons will be performed 
using the student t-test. Six t-tests will be performed per parameter between each 
treatment group. However, this will exponentially increase the risk of an alpha error. This 
will be corrected for using the Bonferroni correction in which the original p-value of 0.05 
will be divided by the number of tests being run which will generate the new p-value for 
significance.  
Initial statistical analysis will be on combined data for participants within each 
treatment group. The hope is that there will be no difference between treatment groups in 
resulting questionnaire scores to confirm that randomization was effective and that no 
groups had a disproportionately large number of high risk individuals. However, if there 
is significant difference among any parameter measured for each treatment group 
resulting from the student t-test, then further group stratification for demographics will 
occur. Within each treatment group, patients of different nationalities will be separated 
and summary statistics performed on the compiled data for 6mo and 12mo visits.  Student 
t-tests within treatment groups will occur to confirm if there is a significant difference 
between participants of each group.  
Confounders will not be adjusted for during statistical analysis for primary study 
results. However, they will be listed as limitations within the Discussion section of this 





Timeline and resources 
Preclinical Phase: 1 year 
Initial goals of this phase will be to obtain IRB approval of consent and study design 
and obtain funding. It will also be necessary to find a 3rd party triple blinding vendor. 
REDCap database access will be established and confirmation that each study parameter 
can be accurately recorded. Study drug capsules will be created during this phase. 
Required personnel will include: Primary Investigator -Elizabeth Fiorentino PA-S, co-
investigators- primary care providers at BMC Family Health, a research coordinator, 
laboratory personnel, and a statistician. Office space with computer access will be a 
necessary resource.  
 
Clinical Phase: 2 years 
Goals of this phase will be to consent and complete treatment period (1 year) for 
100 participants. It will be necessary to maintain data collection and data entry into 
REDcap per participant for each visit. Required personnel will include: Primary 
Investigator- Elizabeth Fiorentino PA-S, co-investigators-primary care providers at BMC 
Family Health, a research coordinator, a phlebotomist, and laboratory personnel. Office 
space with computer access to REDCap and Epic, as well as outpatient exam rooms, will 
be required resources during this phase. For sample collection it will be necessary to have 
ample supply of 25ml purple top EDTA tubes. Additional required resources will include 
a laboratory for blood collection/processing, specially trained lab technicians for 




Data Analysis: 6 months 
Goals of this phase will be to compile and perform data analysis on parameters 
within each treatment group and between treatment groups. Required personnel will 
include: Primary Investigator- Elizabeth Fiorentino PA-S, a research coordinator, and a 
statistician. Office space with computer access will be a necessary resource.  
 
Institutional Review Board 
This submission to the Boston University Medical Center IRB is to request 
expedited approval per Expedite Category 2a. This trial would be appropriate for 
expedited approval because this research has minimal medical risk and would not place 
subjects at risk of criminal or civil liability, damage their financial standing, 
employability, insurance, reputation, or breech confidentiality. While the study is 
designed to examine xylitol supplementation as an intervention, xylitol is a safe 
compound that is currently FDA approved as a food additive or sweetener. The major 
side effect being bloating or diarrhea when given in large doses, that exceed the max 
dosing in this study. Due to the safety and accessibility of xylitol in many food products, 
this intervention would not raise the trial to Full Board review. This trial would fall under 
Expedited Category 2: collection of blood samples by venipuncture. The blood collection 
would be from healthy, nonpregnant adults who weigh at least 110lbs. The amount of 
blood drawn per visit (every 61 days for 1 year) would be 100ml and would not exceed 
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the limit of 550ml/8week period and collection would not occur more frequently than 





 Limitations of this study include a relatively small sample size compared to the 
number of Americans affected with type 2 diabetes nationwide. Furthermore, including 
patients who do not have any additional comorbidities further narrows the study 
generalizability, since type 2 diabetes tends to co-occur with hypertension, 
atherosclerosis, and hyperlipidemia.65 Although the target population at BMC is highly 
representative of the demographic within the United States who are most affected with 
type 2 diabetes, this is an underserved community who may struggle with study schedule 
adherence for 1 year. To address this risk of premature study dropout patients will be 
incentivized with prepaid bus passes for each visit date. With the average annual dropout 
rate ~ 10%, there is a risk of losing 5 participants per year (assuming average enrollment 
of 50 patients each year). Future studies could address this risk by increasing overall 
sample size. Additionally, there are also large Spanish speaking and Haitian Creole 
speaking only populations of patients at BMC who would not be eligible for this study 
due to the consent being English only. Future goals of this study will also be to translate 
the consent form to Spanish and Haitian Creole.  
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Xylitol is becoming more popular as a natural alternative sweetener and because 
of this it can be accessed easily in everyday life outside of the trial. This causes a 
potential for misclassification bias since participants could consume more xylitol daily 
than allocated per their treatment arm while on study. To address this issue, the xylitol 
fraction within the urine will be measured at Visits 4 and 7 (at 6mo and 12mo 
respectively). An additional variable is not standardizing patient’s diet and exercise 
regimens during the study, which could independently affect their blood sugar outcomes.  
There are also many metabolic factors that affect fasting blood glucose and 
HbA1c that will not be measured in this study due to complexity of measurement, study 
funding, and available resources. The study parameters will be measured at 6mo and 
12mo in order to simplify the statistical analysis while focusing on key timepoints during 
treatment. Although this method may increase the risk of data being affected by 
measurement error, it would reduce the probability of averaging out treatment effects if 
many visit results were averaged together into one timepoint. In order to address the 
chance of measurement error in parameters that are being analyzed using 
radioimmunoassay technique (GLP-1,CCK, and SOD), specially trained lab technicians 
will be required. These studies will be easily obtained from patients, however, through 
venipuncture and plasma collection which minimizes bodily risk to participants. 
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The strengths of this proposal include being the first study to measure the long-
term effects of xylitol in humans with type 2 diabetes as well as to investigate parameters 
of carbohydrate metabolism and free radical scavenging ability. These factors not only 
have an effect on fasting plasma glucose and Hba1c but also on comorbidities from the 
disease, including neuropathy, nephropathy, and retinopathy. Since xylitol is also a 
naturally occurring substance, it has low medical risk when taken daily. To minimize 
adverse effects, this study will maximize the dosing at 10% which has previously been 
shown to be the threshold of tolerability.42  
 
Summary 
 The incidence of type 2 diabetes in the United States has been rising over the last 
century, most notably since 1958.1 This rise has been linked to the obesity epidemic 
which appears to have started around the same time that artificial sweeteners, such as 
high fructose corn syrup were used to enhance soft drinks.5 Within the United States the 
populations most commonly affected by this disease include American Indians, Alaskan 
natives, and non-Hispanic blacks with prevalence also increasing at ages over 45 years.16 
Type 2 diabetes is a disease with devastating complications. It is alone a major 
cause of end stage renal disease, retinopathy, and lower limb neuropathy often resulting 
in amputations.5 The current medical treatment for stabilization of blood sugar includes 
oral and injectable agents such as metformin and insulin. However, a healthy lifestyle 
conscious of diet and exercise has been shown to have profound effects on HbA1c.7,9  
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Xylitol is a natural alternative sweetener that has been shown to have antidiabetic 
qualities such as a low calorific value with 40% fewer calories than sucrose, as well as a 
reduced glycemic index of 7 compared to 60-70 for sucrose. Additionally, xylitol allows 
for a slow release of glucose into the bloodstream so it does not raise insulin significantly 
helping to reduce insulin resistance.43,45 This knowledge has paved the way for research 
into natural alternatives to replace artificial sweeteners. 
 Through the review performed in this thesis, it has been found that xylitol’s 
antidiabetic effects have mainly been tested on animal models, predominantly STZ 
induced type 2 diabetic rats.49 Studies have shown that xylitol can induce increased 
release of GLP-1 and CCK, hormones that are responsible for reducing stomach 
emptying, post-prandial glucose release, and stimulating protein and fat digestion.42 
Additional research has also found that xylitol supplementation can significantly reduce 
blood glucose levels.11 One study in particular fed STZ induced rats xylitol 
concentrations of 2.5%, 5%, and 10% and found that xylitol increased SOD activity in all 
organs.55 SOD is an important cellular regulatory factor that helps to reduce oxygen free 
radicals, which wreak havoc on internal cellular structures leading cell and ultimate tissue 
damage. Tissues most often affected include the retina, kidney, and nerve.30 It was 
intriguing to learn that xylitol can also help to reduce osteoporosis and increase collagen 
within the skin which can further halt diabetic complications. 41,47 
 While research has proven animal models to be useful tools for studying the 
genetic, endocrine, metabolic, and morphologic changes of type 2 diabetes in a short time 
span, there are no species in which the disease functions in a mechanism are identical to 
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those in humans.12,13 STZ is beneficial in rat models in that it allows for injected animals 
to develop non-fasting hyperglycemia without significant changes to plasma insulin level 
which provides an opportunity to study the disease in a physiologically similar pathway 
to humans, however this can only take research so far.49 Studies into the antidiabetic 
effects of xylitol have also been limited to short timespans and small study populations. 
At this time, there is a strong need for large-scale long-term studies of xylitol in type 2 
diabetic humans. 
 This project proposal will be a study of the effects of daily xylitol use over 1 year 
in 100 volunteers newly diagnosed with T2DM and whose blood sugar has not yet been 
adequately controlled with diet or medication. These patients will be chosen from BMC 
Family Medicine, a program which provides care for primarily underserved minority 
groups within the Boston area. This will provide a representative sample of patients to 
those most affected with type 2 diabetes in the United States. Patients will be randomized 
to treatment with either placebo, 2.5%, 5%, or 10% xylitol daily in a triple blind fashion. 
The goal of this study is to directly measure the long-term effect of varying 
concentrations of xylitol on blood sugar control in type 2 diabetes. This study will also be 
useful in following post prandial simple carbohydrate metabolism and superoxide free 
radical scavenging ability, which are important in preventing or limiting diabetic 
complications. 
For these study goals, the parameters of HbA1c, FBG, GLP-1, CCK, and SOD 
were chosen. These parameters have been shown by previous studies in rats to be 
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positively affected by xylitol. It is hopeful that similar results will be seen on human 
participants, which will stimulate further important research. 
 
Clinical and/or public health significance 
Type 2 diabetes is a devastating disease with many preventable risk factors. 
Morbidity and mortality from the disease arise from prolonged hyperglycemia which can 
cause major and irreversible systemic affects. Patients affected with complications from 
diabetes often experience debilitation from retinopathy, nephropathy, and neuropathy. 
This leads to difficulty in performing activities of daily living causing increased caretaker 
burden, rising healthcare costs, and overall decrease in productivity, affecting patients, 
their families, and the U.S economy. By finding dietary modifications that can easily be 
incorporated into a patient’s daily life, we may be able to change the outlook for this 
disease on the patient level and on a large scale, as a nation. Xylitol has been shown to be 
superior to sucrose and artificial sweeteners in metabolic parameters, glycemic index, and 
health outcomes.  
The goal of this proposed trial will be to show that blood sugar levels and 
metabolic parameters in newly diagnosed diabetic patients can be improved by daily 
xylitol use. If successful, this will further push the need for replacement of artificial 
sweeteners with xylitol in many commercially bought food products. Furthermore, it is 
hoped that this evidence will encourage physicians to implement xylitol supplementation 
in the diets of their type 2 diabetic patients. More importantly, pre-diabetic patients or 
those suffering from metabolic syndrome could begin use of xylitol daily as part of a 
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lifestyle management plan to help prevent diabetes all together. Not only could xylitol be 
useful in augmenting medical therapy to maintain blood sugar levels but could help to 















Appendix II: Grading of adapted Nutrition and Eating Habits Questionnaire 










13. *ungraded 19. 0pts=no 
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14. 1pt for each 
food plan  
20. 0pts=no 
1pt=yes 
3. 1pt for each 
box 
checked 
9. 1pt for each 
meal eaten 
>4x away 





















6. 1pt=other 12. 0pts=no 
1pt=yes 
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